drugset / Trial / NCT06701825
Effectiveness and Cost-effectiveness of a Pre-emptive Genotyping Strategy in Patients Receiving Tacrolimus
Phase 4
Recruiting
114 enrolled
Instituto de Investigación Hospital Universitario La Paz
Instituto de Salud Carlos III · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
This is a phase IV multicentre adaptive single-blinded randomized clinical trial to evaluate if preemptively genotyping populations at pretransplant chronic kidney disease susceptible of receiving tacrolimus therapy is effective, cost-effective, and feasible within the Spanish National Health System when compared to the current standard of care. This trial is nested within the iPHARMGx master protocol.
Timeline
- Start
- 2025-06-02
- Primary completion
- 2026-10-01
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tacrolimus | Small molecule | — | — |